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CHAPTER 14 
Kidney Transplantation in Pittsburgh: Experience 
and Innovations 
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The first kidney transplant at the University of Pitts-
burgh was performed in 1963. but it was not until 1977 
that kidney transplants were done on a regular basis. 
Since then the University of Pittsburgh has developed 
into a major transplant center. In 1986 alone 271 kidney 
transplants, 344 liver, 104 heart, and 15 heartllung 
transplants were performed at the University Health 
Center of Pittsburgh. 
The data presented here are maintained on a newly 
developed center-oriented computerized transplant 
data management system. A scoring system for equi-
table allocation of kidney transplant organs is an in-
tegral part and will be discussed further. 
MATERIALS AND METHODS 
From 1977 to the end of May 1987. 1.243 cadaveric 
kidney transplants. 17 kidney transplants from living re-
lated donors. and 16 multiorgan transplants including a 
kidney were performed at the University Health Center 
in Pittsburgh. Azathioprine and steroid immunosuppres-
sive baseline treatment was routinely used until a ran-
domized trial versus combined CsA and steroid treat-
ment was performed in early 1981. This was followed 
by the formal introduction of CsA and steroids as the 
baseline immunosuppressive treatment. Azathioprine 
and steroids remained the first choice only for living re-
lated kidney transplants. Since November 1984 the 
murine monoclonal antibody OKT3 (ORTHOCLONE 
OKT3. ORTHO Pharmaceutical Corporation. Raritan. 
NJ) has been used for treatment of severe rejection 
episodes. 
Statistical analysis was performed using the 
SPSSPC (SPSS/PC Software Inc .• Chicago, IL) (1) and 
BMDP/PC (BMDP Software Inc.. Los Angeles. CAl 
software packages. Statistical analysis of differences in 
actuarial survival among groups was done by the Bres-
low (generalized Wilcoxon) and the Mantel-Cox 
(generalized Savage) test. The Breslow test is weighted 
towards earlier events and the Mantel-Cox test towards 
later events (2). 
For analysis of transplant outcome in various 
groups. all grafts or patients lost were included for 
analysis. No patient was omitted. even if the graft was 
lost because of reasons presumably unrelated to 
transplantation. Follow·up of patient data continued until 
the end of July 1987. When not stated otherwise. ac-
tuarial survival is reported for the one-, 2·, and 5·year 
periods. 
RESULTS 
Demographics 
The age of the kidney transplant patients ranged 
from 0.6 to 73.6 (mean 37.9 ± 4.5 SO years). Of these 
patients. 1.104 received 1 .276 cadaveric kidney 
transplants; 985 of these were primary cadaveric 
transplants, 258 cadaveric retransplants. 16 combined 
organ transplants including a kidney. and 17 living re-
lated kidney transplants (Table 1). Of the pediatric age 
group. 87 patients «18.0 years. mean 12 ± 4.6 SO 
years) received 112 grafts and 1.017 patients belonging 
to the adult patient group ( ~ 18.0 years. mean 40.4 ± 
12.6 SO years) received 1.164 grafts. Of these. 12 were 
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below 5 years and 181 equal or over 55 years. Seven 
hundred seventy-seven kidney grafts were transplanted 
into male versus 499 grafts into female recipients. 
Table 1. Cadaveric kidney transplants 
performed at the University of Pittsburgh 
between 1977 and May 198r. 
Multiorgan Transplants Including the 
Kidney 
;:;F"~"D:D;D~~~~""""_ ~ _::. _J.< ............. -,"'-' , c, .. "', .... , .. ~ '" 
Ten combined liver/kidney, 3 of them in the pediatric 
age group, one hearVkidney, and 5 pancreaslkidney 
transplants were performed using organs from the 
same donor. Seven of the combined liverlkidney 
recipients are currently alive with 6 patients having 
functioning kidneys (3). Of the pancreaslkidney 
recipients 4 are stili alive with functioning kidney grafts. 
The hearVkidney recipient died 3 months following the 
combined transplant procedure. 
Analysis of panel-reactive antibody (PRA) and 
donor-reactive crossmatch data in combined liverlkid-
ney transplants has shown in some patients a sig-
nificant decrease in PRA and donor-reactive antibodies 
starting immediately after induction of blood flow 
LTransplant 
~ 
%'i Year 
1977 
I 1978 I r 1979 
1980 I 1981 
I 1982 1983 1984 1985 
I 1986 1987b 
i Total 
Total 
Number 
17 
25 
42 
45 
100 
118 
160 
204 
175 
263 
94 
1243a 
Primary Retransplants 
Transplants ' , t1 
16 1 
18 7 
37 5 
39 6 
69 31 I 
97 21 
135 25 ~ 164 40 . 
138 37 
sD~ 
200 63 
J 72 22 
985 258 M ,through the liver donor. Three recipients had a strong 
donor-positive crossmatch. In 2 patients the donor-
specific antibody titer was decreased after the liver 
transplant. The kidneys from the same donor 
transplanted shortly thereafter were not aHected by 
humoral rejection. The third patient presented with per-
sistently high levels of donor-specific antibodies. The 
kidney graft in this patient did not begin to function (3,4). 
Ii' a Additional 17 living-related and 16 combined; 
kidney transplants were performed. ' 
b From January to the end of May 1987. 
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Figure 1. Actuarial graft survival of primary cadaveric kidney 
transplants using azathioprine or GsA and steroids as baseline 
immunosuppressive treatment (Breslow p<O. 000 1, Mantel-Cox 
p<O.OOOt). 
Survival Analysis 
Azathioprine versus GsA 
One hundred forty-one primary, 
cadaveric kidney transplants were 
performed USing azathioprine and 
steroids as the baseline immunosup-
pressive therapy. One-, 2- and 5-
year actuarial graft survival was 
58.9%, 48.2%, and 36.1%, respec-
tively. Since the introduction of CsA 
and steroid treatment in 1981, 844 
patients received primary cadaveric 
kidney transplants. Actuarial graft 
survival was 74.1%, 67.8%, and 
52.7%, respectively (Breslow 
p<O.0001, Mantel-Cox p<O.0001) 
(Fig. 1). 
One, 2-, and 5-year actuarial 
patient survival of primary cadaveric 
kidney transplants in the 
>K----IKI-II-~D---.... 
azathioprine era was 77.7%, 72.6%, 
and 63.6% while 91.3%, 89.2%, and 
83.3% in the CsA era. 
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veric grouped by the year 
The primary cadaveric kidney 
transplants when divided into various 
years of transplantation showed 
again a definitive improvement 
during recent years since the intro-
duction of CsA. One-, 2- and 5-year 
actuarial graft survival for 71 
transplants performed during 1977 to 
1979 was 61.9%, 47.9%, and 33.8%. 
From 1980 to 1982, 205 transplants 
showed 68.6%, 61.5%, and 48.2% 
graft survival. Since 1983, 708 kid-
neys were transplanted with a sur-
vival of 73.9%, 67.7%, and 59.5% (at 
4 years) (Breslow p=0.009, Mantel· 
Cox p=O.OOI) (Fig. 2). 
of transplantation. There is a definite improvement in survival since 
the introduction of CsA in 1981 (Breslow p=O. 009, Mantel-Cox 
p=O. 00 1). 
Retransplantatlon 
Two hundred and one second, 30 third, 4 fourth, and 
one fifth cadaveric kidney transplants were periormed 
during the CsA era. Many of the patients had previous 
transplants at other institutions. One·, 2- and 5-year ac· 
tuarial graft survival for second transplants was 66.2%, 
57.6%, and 42.7% and for third transplants 59.7%, 
55.5%, and 47.5%. A single fourth kidney graft (25%) 
continued to function at these time intervals and a fifth 
transplant was lost at the day of transplantation (Fig. 3). 
4th Graft (n=4) 
LIVing-Related Transplants 
Living-related kidney transplants were performed at 
a very low rate of only 17 transplants (1.3%) since 
1977, with only one living-related transplant since 1983. 
All used azathioprine as the basic immunosuppressive 
drug. Complete follow-up data were available for 16 of 
these. The survival of living-related kidney transplants 
was not improved (5-year actuarial survival of 53.3%) 
over cadaveric transplants with CsA. 
Recipient and Donor Age 
.'. . 0··0\' ..... 1: . " .. <'t:2o?'·:" 3"'''''''''4 "~"Rv:4DDDD 6 
In recipients age 55 or older, 135 
primary cadaveric kidney transplants 
were performed during the CsA era. 
Actuarial one·, 2- and 5-year graft 
survival was 71.7%, 68.1%, and 
55.1%. This did not differ from the 
survival of 651 grafts transplanted in 
the patient group 18 to 54.9 years of 
age. Younger recipients showed a 
lower survival with 63.6%, 60.0% 
and 50.7% (at 4 years) for 50 
recipients age 5 to 17.9. For 8 grafts 
in recipients under 5 years of age. 
survival was 16.7% at one to 3 years 
(Fig. 4). 
Years ml~ntC!fgKApl~ntKKKKIK" .... I~K~ 
....., .. -.. IK~ .. -~-KKK-K-K"K~~~K 
Figure 3. Actuarial survival of primary and retransplants in 
cadaveric kidney transplantation during the CsA era. A fifth 
transplant was lost at the day of transplantation. 
.. 
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Recipient Age 
• ~R years 
• 18-54.9 years 
.... 5-17.9 years 
~ <5 years 
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Figure 4. Effect of recipient 
age on actuarial survival of 
primary cadaveric kidney 
transplants under GsA. 
Figure 5. Donor age and 
actuarial survival of primary 
cadaveric kidney transplants 
using GsA. Note that organs 
harvested from donors over 
age 55 showed a first inferior 
but then similar survival to 
that of grafts harvested from 
donors age 5 to 55. Kidneys 
harvested from donors under 
5 years of age showed an 
inferior performance (see 
Fig. 6). 
Figure 6. Survival of kidneys 
harvested from donors under 
5 years of age analyzed 
according to recipients' age. 
Note that grafts of these 
young donors showed 
inferior survival in the very 
young recipients with age 
under 5 years. When used in 
recipients over age 5 years 
the survival was still slightly 
less than survival of grafts 
from donors over 5 years of 
age (see Fig. 5). 
-----------------------------...................... ------------------------~--
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.... -'" survival (Breslow p=0.007. Mantel-
~----------------------------------~ Cox p=0.002) (Fig. 6). 
There was no disadvantage in the longer follow-up of 
18 grafts harvested from donors 55 or older even when 
the earlier function was slightly diminished. Long sur-
vival was similar to transplants using grafts harvested 
from donors of age groups 5 to 17.9 and 18 to 54.9. In-
stead. survival was inferior for 44 donor kidneys har-
vested from donors 5 years or younger (Fig. 5). Further 
analysis revealed that grafts of these very young 
donors, when used in recipients over 5 years of age. 
showed inferior survival than grafts from older or adult 
donors. Grafts of these very young donors when used 
in recipients under 5 years showed a drastically inferior 
Recipient 
Presensitization 
In the CsA era 774 primary 
cadaveric transplants were per-
formed in recipients with a most 
recent PRA of zero to 39.9%. One-, 
2- and 5-year actuarial graft survival 
was 75.7%, 70.0%, and 53.5%. For 
66 transplants in patients with a 
most recent PRA of 40.0% or 
higher, actuarial survival was 
55.7%, 46.3%, and 46.3%. respec-
tively (Breslow p<0.0001. Mantel-
Cox p<O.OO1). 
Historically highest PRA values 
of zero to 39.9% were found in 658 recipients. Survival 
was 75.4%. 70.5%. and 55.5%. For 171 recipients the. 
highest PRA was 40.0% or higher, with 68.6%. 58.9%, 
and 42.8% survival (Breslow p=O.005. Mantel-Cox 
p=0.004). 
ABO, Sex 
Five hundred fifty-two transplants were performed in 
blood group 0 patients. 502 in blood group A patients, 
162 in blood group B patients, and 59 in blood group AB 
patients. No diHerences in actuarial graft survival for 
various ABO groups of the recipient or of the donor 
were detected. In contrast to pre-
1.0 ...... ____________ -... vious reports (5) female recipients 
or grafts harvested from female 
donors showed a trend toward a 
slightly better survival (p=NS) (Fig. 
as 0.9 
~ ... 0.8, 
::J 0.7 
U') 0.6 
~ 0.5 
i 0.4 
:s 0.3 • Previous hemodialysis (n=615) 
C 0.2 • Previous Peritoneal Dialysis (n=98) 
::J 0 1 .. Previous Continuous Ambulatory 
(.) • Peritoneal Dialysis (n:59) 
• 0:'0"' ... " ~ ___ .....-_ ...... _....-____ ...,... .... 
Figure 8. Survival of 772 primary cadaveric kidney transplants 
according to type of previous dialysis of patient (Breslow p=NS, 
Mantel-Cox p=NS). 
7) in our series. 
Dialysis 
For 772 of the primary kidney 
transplants during the CsA era. in-
formation about the principal type of 
former dialysis was available. Kid-
ney recipients with previous 
hemodialysis showed a trend toward 
a better survival than recipients with 
former peritoneal or continuous am-
bulatory peritoneal dialysis (Fig. 8). 
There was no significant diHerence 
I 
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. 1.0 -.... _______ .":_""'_', .:.:.:..::. .;;;.:,.:. ___ ...., criteria, patients are activated on the 
candidate list. Lowest risk was not 
the primary guiding factor in patient 
selection. 
'(Q0.9 
~DMKU 
:::s 0.7 
~IMKS 
K~ 0.5 
;:: 0.4 ca, 
Right Donor Kidney (n=128) 
Left Donor Kidney (n=98) 
~ ... ... . 
En bloc Kidney (n=5) 
The introduction of combined 
CsA and steroid treatment as the 
baseline immunosuppressive 
medication significanlly enhanced 
the results of kidney transplantation 
in our series. But various other 
OS 0.3 
E'O.2 
:::s 0.1 ~b~~~D·I ______________________ ~ 
, preexisting recipient or donor condi-
tions may still have an important eft 
fect on kidney transplant survival 
and should not go unrecognized. 
Also in our series, a lower PRA an-
tibody level was a main determinant 
for better success of the kidney 
transplant. HLA showed a trend 
towards enhanced survival for bet· 
Figure 9. Actuarial survival according to donor kidney side. Data 
was available for 231 of the most recent primary cadaveric 
transplants under CsA (Breslow p=NS, Mantel-Cox p=NS). 
in transplant groups according to length of previous 
dialysis, but a trend toward a better survival for patients 
with shorter dialysis history was noted. 
Donor Kidney Side 
For 231 of the most recent primary kidney 
transplants in the CsA era, the side of the harvested 
donor kidney was known, Actuarial one· and 2·year sur-
vival for 128 right donor kidneys was 75.6% and 75,6%; 
98 left donor kidneys were transplanted with a survival 
of 70,8% and 61,8%, Five en bloc kidney transplants 
showed an inferior one-year survival of only 40,0% 
(Breslow p=O,036, Mantel-Cox p=O,039)(Fig. 9). 
HLA 
Throughout the analysis there was a trend towards 
enhanced survival for better HLA-A, B or DR matched 
kidney allografts. This effect was not statistically sig-
nificant. presumably because of relatively low numbers 
in the analysis (Figs. 10-' 2). 
DISCUSSION 
Many of the patients transplanted at the University of 
Pittsburgh were referred from other institutions, either 
having prevIous transplants performed or because of 
clinico-pathologic circumstances presenting a higher 
risk for transplant outcome. Once feasibility for 
transplantation was established using predefined 
ter-matched grafts, but presumably 
because of relatively small numbers, this trend was not 
statistically significant. 
One main advantage of CsA was described to be the 
enhanced survival of older transplant recipients (6). 
Also in our series older recipients aged 55 or more 
showed a good survival similar to that of younger adult 
recipients. 
Combined liver/kidney transplants have been shown 
to offer a favorable treatment modality for patients with 
endstage liver and renal disease. It is important to note 
that 2 of the kidney allografts performed against a posi-
tive donor·specific crossmatch seemed to be protected 
against a deleterious immune response by the liver al-
lograft transplanted only hours before (3,4), 
Living-related kidney transplants were almost totally 
abandoned at our institution With only one living-related 
transplant since 1983. Reasons for this approach are 
the increased availability of cadaveric donor organs, the 
improved results with cadaveric transplants under CsA, 
and the possible risks to the living donors (7). The latter 
seems of major importance since an increased in-
cidence of hypertension might appear in these donors 
and long-term follow-up studies are still rare. This is of 
special significance since living-related donors are in 
perfect health. In addition psychological and other un-
discovered factors influencing the decision of a parent. 
brother, sister, or other living donor might not be fully 
appreciated by the surgeon. Nevertheless, in countries 
with a more limited availability of cadaveric donor or-
gans, another approach must depend on the surgeon 
and patient decisions. 
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Figure 10. Actuarial survival of 
primary cadaveric kidney 
grafts with CsA when grouped 
according to mismatches at 
the HLA-A locus. Transplants 
lost because of technical 
problems. poor patient 
compliance. or presumably 
unrelated factors leading to 
patient death were not 
considered for this analysis 
(Breslow p=NS. Mantel-Cox 
p=NS). 
Figure 11. Actuarial survival of 
primary cadaveric kidney 
grafts under CsA when 
grouped according to 
mismatches at the HLA-OR 
locus. Transplants lost 
because of technical 
problems. poor patient 
compliance. or presumably 
unrelated factors leading to 
patient death were not 
considered for this analysis 
(Breslow p=NS. Mantel-Cox 
p=NS). 
Figure 12. Actuarial survival 
of primary cadveric kidney 
grafts under CsA when 
grouped according to 
mismatches at the HLA-A. 
-B and -DR loci. 
Transplants lost because of 
technical problems. poor 
patient compliance or 
presumably unrelated 
factors leading to patient 
death were not considered 
for this analysis (Breslow 
p=NS. Mantel-Cox p=NS). 
, 
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In reviewing the type of dialysis, a trend towards bet-
ter survival of a following kidney transplant in patients 
on hemodialysis versus peritoneal or continuous am-
bulatory peritoneal dialysis was noted. In addition a 
shorter dialysis history seemed to improve kidney graft 
survival. How far this was influenced by other cir-
cumstances leading to a particular dialysis method or 
by the dialysis method itself could not be determined 
from our series. It seems likely that patient conditions, 
such as hemodynamic instability, no access sites for 
hemodialysis, and higher presensitization with HLA an-
tibodies and a subsequently longer waiting time, were 
influencing the outcome. If possible hemodialysis might 
suggest the better choice, but further studies are 
needed. 
Interestingly, the donor kidney side showed a benefit 
in survival for right donor kidneys in comparison to left 
donor kidneys. En bloc transplants showed an inferior 
survival possibly because of additional size considera-
tions, preexisting anatomic factors, and increased tech-
nical difficulties. Both these findings need to be 
evaluated in a larger transplant population in order to 
draw firm conclusions. 
TIMY - Transplant Information 
Management System 
A center·orlented computerized transplant informa-
tion management system (TIMY) was developed for 
processing the kidney transplant data. The system 
focuses on the everyday informational needs of both 
the clinician and the researcher. Therefore the com-
puter must be user friendly and readily accessible to all 
levels of the departmental staN according to their 
specific information needs. Similar systems are current-
ly in use for the liver transplant program and to some 
extent for the heart transplant service. 
Using the DA T AEASE database program 
(DATAEASE INTERNATIONAL, Trumbull. CT), TIMY 
was designed and implemented using an IBM-AT with a 
30 megabyte harddisk. Part of the data was transferred 
from a previously existing database. Many of the data-
entry fields are choice fields which help to eliminate 
data-entry errors. with additional precoding of fields al-
lowing for convenient statistical analysis. System 
modifications required to customize the database ac-
cording to the needs of the individual transplant center 
are readily accomplished. 
The system design covers the candidacy. transplant. 
and the follow·up phases. Data can be entered in the 
appropriate forms (Figs. 13-15) with easy movement 
between the various patient records. In addition, ad· 
dresses and telephone numbers of referring physicians, 
patients, and their home dialysis centers are stored in 
specific files and used to print the weekly candidate list. 
Various established reports are available for clinical and 
research tasks. Included are the comprehensive can· 
didate listings, regular summary reviews, and statistics 
(Figs. 16·17}. 
The database is available to the transplant coor· 
dinators via a laptop computer. Therefore pertinent 
patient data can be reviewed from any telephone con· 
nection, facilitating the coordinators' work during nights 
and weekends. The dynamic nature of the data requires 
constant updating and the coordinator can review any 
data changes since the last printing of the candidate list. 
The system structure encompasses the data neces-
sary for reporting to government agencies as well as to 
the UCLA and CTS Kidney Transplant Registries. The 
electronic data transfer via diskettes or modem to the 
UCLA Kidney Transplant Registry and to the CTS study 
at the University of Heidelberg, West·Germany, is cur-
rently being implemented. 
Scoring System 
In order to facilitate the allocation of the best suitable 
transplant candidate when a donor organ is offered. an 
integral computerized scoring system was developed 
as an objective allocation method (8). The results do not 
mandate, but facilitate the decision-making process of 
the surgeon. Currently in Pittsburgh the Transplant 
Organ Procurement Foundation is running this scoring 
system. 
Various factors were thought to play an important 
role in the assessment of a suitable candidate. Of 
these, the 5 most significant are used in the scoring 
system: time of waiting, quality of HLA antigen match. 
presensitization state with PRA, medical urgency, and 
logistical factors. Since donor and reCipient should be of 
the same blood group with only rare exceptions, renal 
candidates are grouped according to whether their 
blood type is 0, A. B, or AB. Candidates who weigh less 
than 27 kg or are 10 years or younger are listed 
separately. Sera from all candidates of the appropriate 
blood type and size are matched against lymphOCy1es 
from the donor of the offered kidney. A negative 
crossmatch, connoting the absence of antidonor 
Cy1otoxic antibodies In the reCipient serum, is a neces· 
sary condition for placement on the list of potential can-
didates. 
The waiting score is determined as a rank order of 
waiting time, established from the date of referral for 
consideration of transplantation. A maximum of 10 
points is awarded to the candidate waiting for the 
longest period, with fewer points given for shorter waits. 
The quality of antigen match points is determined by 
the grade of histocompatibility at the HLA-A, e, and DR 
loci. Two points are given for each antigen matched, 
with a score of 12 being possible. 
The present state of alloimmunization, as defined by 
the most recent PRA level, is used for calculating the 
PRA score. One point is given for each 10% PRA value 
up to a maximum of 10 points. 
The medical urgency score is used in cases where 
dialysis is not a feasible option for. the patient, so 
transplantation within a short period of time is essential. 
This is used, for example, in patients whose access 
sites for dialysis had been exhausted. A total of 10 
points can be assigned to such a patient. 
A maximum logistics score of 6 points can be 
awarded for logistical factors based on the ease and 
rapidity with which the transplantation could be per-
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formed. For example. if a kidney was offered near the 
end of its permissible storage time. logistical points 
might be given to a candidate whose proximity to the 
hospital and history of recent dialysis could permit 
prompt transplantation. 
As stated above, the result of the scoring system 
does not mandate. but facilitates the selection of an ap-
propriate candidate for this particular donor organ. Cer-
tainly additional medical circumstances. such as CMV 
status of donor and recipient. size limitations. etc. have 
to be considered. When there is a deviation from the 
computerized scoring result. an explanation is docu-
mented. Scoring results and overriding explanations are 
routinely reported to community boards for review pur-
poses. Since its introduction in 1986 this computerized 
scoring system has proven to be a very valuable tool in 
the transplant candidate selection process. 
A similar scoring system is routinely used for can-
didate selection in our liver transplant program (9). A 
system for heart transplantation is currently under 
evaluation. 
TRANSPLANT INFORMATION MANAGEMENT SYSTEM - KIDNEY REGISTRY - DEMOGRAPHICS 
.................................................................................................................... 
10# ______ LAST NAME ______ FIRST NAME ____ _ 
DATE OF BIRTH ___ _ 
SEX RACE _______________ ___ 
BLOOD GROUP ABO __ _ RH ___ _ LEWIS ANTIGEN A ___ B _ 
HLA TYPE A_,_B_,_Bw_DR_,_DQ_._DRw_,_ TISSUE TYPING #_ 
DIAGNOSIS __________ _ 
DATE DIAGNOSIS WAS FIRST MADE __ _ 
COMMENT ___________________________________ _ 
IF PATIENT LOST TO FOLLOW-UP. ENTER DATE OF LAST FOLLOW-UP ___ _ 
IF PATIENT DIED. ENTER DATE OF DEATH _______ _ 
PRIMARY CAUSE OF DEATH 
SECONDARY CAUSES OF DEATH 
2. ________________ _ 
3. ________________ _ 
4. ________________ _ 
5. ________________ _ 
COMMENT 
Figure 13. Every patient entered in the TlMY kidney transplant management system has a pertinent 
record with demographic data. Most of the data is entered in precoded choice fields. which minimizes 
data-entry errors and greatly facilitates later analysis. 
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TRANSPLANT INFORMATION MANAGEMENT SYSTEM - KIDNEY REGISTRY - CANDIDATE DATA 
............................. * .......... *.* •• ** ....... * .......................................... 111 .................................... * ......................... . 
10# LAST NAME FIRST _______ _ 
CURRENT RECORD _ CANDIDACY FOR GRAFT #_ ABO __ ALlEN __ 
PHYSICIAN CODE__ DIALYSIS CENTER CODE__ SEND LETIER __ 
DATE REFERRED __ _ PREFERENCE ______ _ 
LIST STATUS ________ __ URGENCY ___ _ LOGISTICS __ _ 
INSURANCE _______ _ SECONDARY _________ __ 
AGE AGE GROUP ______ TOTAL PREGNANCIES __ LIVE BIRTHS __ 
HEIGHT _ft_in OR _em WEIGHT __ lbs OR _kg 
PRA HIGHEST_ DATE 
HMb_ 
CMV __ 
HBsAg__ HBsAb 
HIV ELISA TESTING 
PRA RECENT_ DATE 
HBcAb __ _ 
WESTERN BLOT 
PRE-KTX BLOOD TRANSFUSIONS WHOLE BLOOD__ PACKED RED CELlS __ 
WASHED CELLS_ FROZEN/FILTERED PLASMA __ PLATELETS __ BUFFY COATS_ 
IF LIVING DONOR, ENTER # OF DONOR SPECIFIC TRANSFUSIONS _ 
DATE OF LAST PRE-KTX TRANSFUSION ___ _ 
START OF DIALYSIS 
NEPHRECTOMY 
SPLENECTOMY 
ADDITIONAL DIAGNOSIS 
HEPATIC 
PULMONARY 
CARDIOVASCULAR 
JUVENILE DIABETES MELLITUS 
ADULT DIABETES MELLITUS 
DIABETIC TREATMENT 
TYPE 
DATE 
DATE 
REASON 
COMMENTS ____________________ __ 
........................................................................................................................................................................ 
Figure 14. Form for candidate information. Additional forms exist for patient address, referring 
physician. and dialysis center. 
TRANSPLANT INFORMATION MANAGEMENT SYSTEM - KIDNEY REGISTRY - TRANSPLANT DATA 
................................................................................................. * ...... *.*.* ........................... *.* ••••• 
ID# _______ LAST NAME _____________ FIRST ___________ _ 
NUMBER FOR THIS GRAFT (GX#)_ TRANSPLANTED ORGANS. ___________ _ 
DATE OF KTX SERVICE DONOR# TRANSPLANT 10# 
AGE AT KTX 
IMMUNOSUPPRESSIVE BASELINE ____________ CyA STARTED DAY __ 
DONOR LOCALITY _________ _ OTHER ____________ _ 
HARVEST MODE ___ _ COLDSTORAGE _______ _ 
MACHINE _______ _ PERFUSATE ___________ _ 
ISCHEMIA TIME WARM DONOR __ min COLD hr_min WARM RECIPIENT_min 
RECIPIENT SURGEON _____ 1 st ASSISTANT ___ DONOR SURGEON __ _ 
INTRA-OPERATIVE-BLOOD-TRANSFUSIONS WHOLE BLOOD PACKED RED CELLS_ 
WASHED CElLS __ FROZEN/FIL TERED PLASMA_ PLATELETS_ 
...................................................................................................•...................... 
DONOR INFORMATION 
LAST NAME ______ FIRST ___________ SEX ____ _ 
WEIGHT _Ibs or _kg AGE __ RACE ___________ _ 
BLOOD GROUP ABO RH __ _ LEWIS ANTIGEN A_ B_ 
--.................. ---_ .... -_ .............. -- -_ .............. --- -_ .......... ------- ....... -- -_. __ .... __ .. -_ .... --- ----_ ...... -- --- -- -- .. ---- --------- ...... --- ---- -_ ....... --_ .. ----- -_ .... -_ .... --_ .. 
RELA TIONSHIP ______ _ DONOR KIDNEY SITE _________ _ 
CAUSEOFDEATH __________ CANCER _______________ _ 
HBsAg_ CMV__ VDRL__ HIV ELlSA__ WESTERN BLOT_ 
OTHER INFECTION IF YES, SPECIFY _____ _ 
RECENT BUN RECENT CREATININE 
TISSUE TYPING # __ HLA TYPE A_,_B_,_Bw_DR_,_DQ_,_DRw_,_ 
DATE OF SERA CROSSMATCH TEST TYPE ___ _ 
AUTOLOGUS CONTROL __ TEST TYPE ___ _ 
.... *.* ....................................................................................................................... . 
RESULTS OF SCORING SYSTEM 
WAITING PRA HLA URGENCY_ LOGISTICS TOTAL 
OVERRIDER __ IF YES. FULL EXPLANATION HAS TO BE GIVEN IN COMMENTS 
INCLUDING 10# OF OVERRIDEN PATIENTS. EXPLANATION HAS TO BE KEPT IN ADDITION 
AS A HARD COPY FOR ALL TIMES WITH SCORING PRINTOUT A IT ACHED TO ITI 
COMMENTS: ______________________________________________ __ 
151 
Figure 15. Data-entry form covering the essential information related to the transplant event and of the 
particular donor. For survival and status information there are additional forms. 
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TRANSPLANT INFORMATION MANAGEMENT SYSTEM - KIDNEY TRANSPLANT REGISTRY 
CANDIDATE LIST AS OF 07107/87 
• BLOOD GROUP 0 • PAGE 1 
.. * ** ............ * ........ * ................... **** .................................................................................................................... . 
Doe. John 10#: 999-99-9999 DATE REFERRED: 12101/86 
ABO: 0 AGE: 53.6 SEX: MALE DOB: 01/01/34 HT: 173 WT: 77.9 
CANDIDACY FOR GX#: 1 STATUS: ACTIVE URGENCY: 
DIAG: Diabetic Nephropathy 
PRA HIGH: 2.0 DATE: 01/01/87 
TISSUE TYPING #: 77777 HLA TYPE: 
HAAB: Neg HBsAg: Neg HBsAb: Neg 
INSURANCES: Slue Cross/Blue Shield 
DIALYSIS: Hemodialysis 
PRA RECENT: 0.0 DATE: 04/07/87 
A 2.3 B 7,62 DR 3.5 
HBcAb: Neg CMV: Neg 
NEPHRECTOMY: None 
COMMENTS: Patient had myocardial infarct in 10/85 
ADDRESS: 1122 Beechwood Ave, Pittsburgh, PA.15219 
PHONE HOME: (412) 999-9999 PAGER: (412) 999-9999 
PHONE WORK: (412) 999-9999 TYPE: VOICE 
RELATIVES: (412) 999-9999 - Susan - aunt 
RELATIVES: (412) 999-9999 - Jack • sister 
DIALYSIS Cbkqb~: ABC PHONE: (412) 999-9999 REFERRING MD: TES 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• * •••••••••••••••• 
Doe, John 10#: 999-99-9999 DATE REFERRED: 05/15186 
ABO: 0 AGE: 39.1 SEX: MALE DOB: 07108/48 HT: 193 WT: 83.4 
CANDIDACY FOR GX#: 2 STATUS: ACTIVE URGENCY: 
DIAG: Polycystic Kidney Disease 
PRA HIGH: 54.0 DATE: 03/19/86 
TISSUE TYPING #: 99999 HLA TYPE: 
HAAS: Neg HBsAg: Neg HBsAb: Neg 
INSURANCES: Medicare 
DIALYSIS: Hemodialysis 
PRA RECENT: 41.0 DATE: 06/29/87 
A 1,28 B 7,60 DR 4, 
HBcAb: Neg CMV: Neg 
NEPHRECTOMY: Yes 
COMMENTS: First kidney transplant in 3/85. rejected after 12 months 
ADDRESS: 1133 Fif1h Ave. Pittsburgh, PA. 15216 
PHONE HOME: (412) 999-9999 PAGER: (412) 999-9999 
PHONE WORK: (412) 999-9999 TYPE: VOICE 
RELA TIVES: (412) 999-9999 - Terry - mother 
RELATIVES: (412) 999-9999 - Greg - brother 
DIALYSIS CENTER: ABO PHONE: (412) 999-9999 REFERRING MD: DVT 
............................................................................................................... 
ETC. ETC. ETC. 
BLOOD GROUP A 
BLOOD GROUP B 
BLOOD GROUP AB 
ETC. ETC. ETC. 
CANDIDATE LIST STATISTICS 
FOR ALL BLOOD GROUPS 
ACTIVE CANDIDATES # 119 100.0 % 
BLOOD GROUP 0 # 57 47.9% 
BLOOD GROUP A # 34 28.6% 
BLOOD GROUP B # 20 16.8% 
BLOOD GROUP AB # . 8 6.7% 
. ..................................................................... 
Figure 16. Weekly candidate listings are printed with comprehensive candidate data for use by 
transplant coordinators, procurement agency, and tissue typing laboratory. 
----------------------------------------------------------_. 
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'. 1. The introduction of combined CsA and steroid 
treatment as the baseline immunosuppressive 
medication significantly enhanced the results of 
kidney transplantation in our series. But various 
other preexisting recipient or donor conditions 
may still have an important effect on kidney 
transplant survival and should not go unrecog-
nized. 
Living-related kidney transplants were almost 
totally abandoned at our institution. Reasons for 
this approach are the increased availability of 
cadaveric donor organs, the improved results 
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